Hydrocodone: Then and Now
Today marks the one year anniversary of hydrocodone becoming a schedule II drug with more restrictive access. Has life been better under these new rules?
Today marks the one year anniversary of hydrocodone becoming a schedule II drug with more restrictive access. Has life been better under these new rules?
Winning is everything – in football and in medicine. Rheumatologists have achieved many successes but still struggle to win against a handful of rheumatic foes. This retrospective examines past wins and losses and helps us to look ahead to a new season.
RA patient complicated by invasive fungal infection with coccidioidomycosis is discussed by Drs. Tesser and Cush
Rheumatoid arthritis affects women in their child-bearing years and many will face the issue of pregnancy and RA management at some point. Here are11 considerations for those managing RA patients who wish to become pregnant.
The prevention of Herpes zoster infections can be challenging in patients receiving immunosuppressives or biologic therapies. Dr. Artie Kavanugh reviews a new, potential advance in vaccination for shingles.
I had just finished going over the prognosis and treatment plan with my newly diagnosed rheumatoid arthritis patient. I asked if she had any questions for me. She did.
Comorbidities often influence the choice of therapies in RA. This elderly man with hepatitis and TB needs aggressive treatment, but what drugs can reasonably be considered?
If you’re going to spend 10-20% of your clinic hours examining and caring for 28 or 68 or 360 joints – it may be instructive to own up to those joints we excel at and take note of the ones we avoid, despise or struggle with.
Adult-onset Still's posses a interestng and diagnostic challeng when encountered. Here are 5 tips to improve your diagnostic acumen for this febrile disorder.
The DRESS syndrome is a rare and sometimes catastrophic disorder resulting from specific drug exposures, including allopurinol, minocycline, INH, anticonvulsants or retroviral agents.
I was recently asked, “what is the best kind of arthritis to have?” My response is based on diagnosibility, treatability and safety of necessary treatment.
Drug efficacy is swiftly proven in phase II and III trials. Yet drug safety requires time, wider exposure, physician education and patient acceptance to be fully established.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.